Medtronic plans to spin off its diabetes unit into a separate publicly traded company within 18 months. The move aims to streamline its portfolio and sharpen focus on high-margin areas like pulsed field ablation and renal denervation.
The new diabetes entity—already comprising 8,000+ employees and 8% of Medtronic’s FY25 revenue—will prioritize innovation in intensive insulin management. Que Dallara, current president of the unit, will serve as CEO of the new company.
Medtronic’s strategy reflects a broader shift toward specialization and shareholder value creation.
Follow MEDWIRE.AI for medtech market updates.
